Clinical Trials Logo

Filter by:
NCT ID: NCT03844828 Not yet recruiting - Cataract Clinical Trials

Clinical Study to Investigate Outcomes of Trifocal Toric IOL POD FT in Asian Eyes

Start date: March 2019
Phase: N/A
Study type: Interventional

Prospective, controlled, single-surgeon, single-center clinical study to compare visual acuity outcomes to data obtained in a similar study by the same principal investigator on the trifocal IOL POD F (study no. PHY1802, ClinicalTrials.gov ID: NCT03688425)

NCT ID: NCT03839823 Not yet recruiting - Breast Cancer Clinical Trials

Study to Compare the Combination of Ribociclib Plus Goserelin Acetate With Hormonal Therapy Versus Combination Chemotherapy in Premenopausal or Perimenopausal Patients With Advanced or Metastatic Breast Cancer

RIGHT Choice
Start date: February 28, 2019
Phase: Phase 2
Study type: Interventional

To compare the combination of Ribociclib plus goserelin acetate with hormonal therapy versus combination chemotherapy in premenopausal or perimenopausal patients with advanced or metastatic breast cancer

NCT ID: NCT03830866 Recruiting - Clinical trials for Locally Advanced Cervical Cancer

Study of Durvalumab With Chemoradiotherapy for Women With Locally Advanced Cervical Cancer (CALLA)

CALLA
Start date: February 15, 2019
Phase: Phase 3
Study type: Interventional

This is a randomized, multi-center, double-blind, placebo-controlled, global, Phase III study to determine the efficacy and safety of durvalumab + Chemoradiotherapy versus Chemoradiotherapy alone as treatment in Women With Locally Advanced Cervical Cancer

NCT ID: NCT03803618 Recruiting - Dengue Clinical Trials

Dengue Effectiveness Study

Start date: September 1, 2017
Phase:
Study type: Observational

This is an observational study that aims to determine the effectiveness of a tetravalent dengue vaccine (CYD-TDV) when given through a community-based immunization program against hospitalized and /or severe virologically confirmed dengue.

NCT ID: NCT03800134 Recruiting - Clinical trials for Non-Small Cell Lung Cancer

A Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Non-small Cell Lung Cancer

Start date: January 30, 2019
Phase: Phase 3
Study type: Interventional

This is a Phase III, randomized, double-blind, placebo-controlled, multi-center international study assessing the activity of durvalumab and chemotherapy administered prior to surgery compared with placebo and chemotherapy administered prior to surgery in terms of major pathological response.

NCT ID: NCT03771040 Active, not recruiting - Asthma Clinical Trials

Masitinib in the Treatment of Patients With Severe Uncontrolled Asthma and Elevated Eosinophil Levels

Start date: December 2016
Phase: Phase 3
Study type: Interventional

The purpose of this study is to assess the safety and efficacy of masitinib (6 mg/kg/day) in severe persistent asthma, uncontrolled with high dose of inhaled corticosteroid and with elevated eosinophil levels.

NCT ID: NCT03732677 Recruiting - Clinical trials for Muscle Invasive Bladder Cancer

Durvalumab+ Gemcitabine/Cisplatin (Neoadjuvant Treatment) and Durvalumab (Adjuvant Treatment) in Patients With MIBC

NIAGARA
Start date: November 16, 2018
Phase: Phase 3
Study type: Interventional

A Global Study to Determine the Efficacy and Safety of Durvalumab in Combination with Gemcitabine+Cisplatin for Neoadjuvant Treatment and Durvalumab Alone for Adjuvant Treatment in Patients with Muscle-Invasive Bladder Cancer

NCT ID: NCT03715790 Recruiting - Clinical trials for Acute Myocardial Infarction

Improve SCA Bridge Study

Start date: November 2, 2018
Phase:
Study type: Observational

The purpose of the Improve SCA Bridge study is to characterize the care pathway flow of post‐acute myocardial infarction (MI) patients as a result of standard assessments of left ventricular ejection fraction (LVEF) in the acute phase (≤14 days post‐ acute MI) and chronic phase (≥40‐90 days post‐acute MI).

NCT ID: NCT03710551 Recruiting - Infant Term Birth Clinical Trials

Happy Smooth Study

Start date: September 26, 2018
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate the stool composition and GI tolerance of an experimental formula with a new fat blend plus L. reuteri vs control formula.

NCT ID: NCT03706690 Recruiting - Clinical trials for Carcinoma, Non-Small-Cell Lung

A Study of Durvalumab as Consolidation Therapy in Non-Small Cell Lung Cancer Patients

PACIFIC-5
Start date: November 27, 2018
Phase: Phase 3
Study type: Interventional

This is a Phase III, randomised, double-blind, placebo-controlled, multicentre study assessing the efficacy and safety of durvalumab compared with placebo, as consolidation therapy in patients with locally advanced, unresectable, non-small cell lung cancer (Stage III), who have not progressed following definitive, platinum-based, chemoradiation therapy.